-transparent.png){kind=logo}
Serum amyloid-A protein (SAA) is the putative precursor of amyloid-A (AA) protein which forms the fibrils in reactive systemic or secondary amyloidosis. By means of a novel immunoradiometric assay, the concentration of SAA was found to be greatly elevated in patients with rheumatoid arthritis and juvenile chronic arthritis and correlated with activity of their primary disease. However, in patients with systemic lupus erythematosus SAA levels were only modestly raised, even in those with severe active disease, unless significant intercurrent microbial infection was also present. In Crohn's disease SAA levels showed a pattern similar to that seen in rheumatoid arthritis, whereas in ulcerative colitis it resembled that of systemic lupus erythematosus. The level of SAA response in these different disorders corresponds with the incidence of reactive systemic amyloidosis in them. These observations support the view that major increases in SAA levels are a necessary condition for the deposition of this form of amyloid and suggest that prospective monitoring of the SAA concentration in predisposing diseases may help to identify those individuals who are most at risk for amyloidosis.
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
January 1985,
Clinical and experimental rheumatology,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
January 1986,
Clinical and experimental rheumatology,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
March 1984,
Thorax,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
November 1984,
The Journal of laboratory and clinical medicine,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
April 1990,
Harefuah,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
January 1979,
Arthritis and rheumatism,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
February 1993,
Clinical chemistry,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
May 2024,
European journal of internal medicine,
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
July 2001,
Lancet (London, England),
F C De Beer, and
R K Mallya, and
E A Fagan, and
J G Lanham, and
G R Hughes, and
M B Pepys
August 1984,
Annals of the rheumatic diseases,
